-  Performance status score of 0 or 1

          -  Measurable disease as per radiographic evaluation

          -  Disease-specific criteria for dose escalation:

               -  Participants with any type of solid tumor for which no treatment is currently
                  available, or

               -  Participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy
                  and have not or are unable to receive stem cell transplant. transfer

               -  Participants may have received up to 5 prior anti-cancer therapies and an
                  unlimited number of prior hormonal therapies.

          -  Disease-specific criteria for dose-expansion Cohort 1:

               -  Participants with previously untreated locally advanced or metastatic NSCLC with
                  a high PD-L1 expression

          -  Disease-specific criteria for dose-expansion Cohort 2:

               -  Participants with metastatic melanoma with at least one prior anti-cancer therapy
                  and progression after PD-L1 therapy

          -  Disease-specific criteria for dose-expansion Cohort 3:

               -  Participants with metastatic gastric, or gastroesophageal junction, or esophageal
                  cancer with at least 1 prior chemotherapy and no prior PD-(L)1 therapy.

          -  Disease-specific criteria for dose-expansion Cohort 4:

               -  Participants with metastatic cervical cancer with at least 1 prior chemotherapy
                  and no prior PD-(L)1 therapy.

          -  Disease-specific criteria for dose-expansion Cohort 5

               -  Participants with diffuse large B-cell lymphoma (DLBCL) with at least 2 prior
                  anti-cancer therapies and have not or are unable to receive allogenic stem cell
                  transplant

               -  Participants with multiple myeloma with at least 3 prior anti-cancer therapies
                  and for whom no treatment is currently available.

        Exclusion Criteria:

          -  History of trauma or major surgery within 28 days prior to the first dose of study
             treatment.

          -  Prior treatment with an anti-TIGIT antibody.

          -  Any active or prior autoimmune disease that required treatment within 3 years of the
             first dose of study treatment.

          -  Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic
             agents, or use of other investigational drugs within 28 days before first dose of
             study treatment.

          -  Discontinued prior immunotherapy for immune related adverse events with a high
             severity.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.